Clinical Trial

Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema

Study acronym: DAPA-DME
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 19, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this clinical study is to explore the efficacy of dapagliflozin as an adjunct to intravitreal anti-vascular endothelial growth factor (anti-VEGF) for enhanced reduction of retinal thickness and vision improvement in patients with diabetic macular edema. The main question the study aims to answer is: Does dapagliflozin reduce the thickness of the macula when combined with the standard of care intravitreal anti-VEGF therapy more than the intravitreal anti-VEGF therapy alone?
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-20.
Trial Details
NCT Number NCT06845163
Lead Sponsor Alexandria University
Conditions Diabetic Macular Edema, Center-involved Diabetic Macular Edema
Enrollment 56 participants
Start Date 2025-02-08
Primary Completion 2026-03 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2025-06-19